TORONTO, April 26, 2012 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (“Transition” or the “Company”) (TSX:TTH) (Nasdaq:TTHI) announced that three ELND-005 poster presentations were presented yesterday at the American Academy of Neurology meeting in New Orleans, Louisiana. These presentations described responder analyses and characteristics, along with findings on the effect of ELND005 on the emergence of neuropsychiatric symptoms.
